Hutchmed (china) Share Discussion Threads

[sportii] 03/3/2021 20:23

Keeping fingers crossed for tomorrow.
Testing time for the patience of the long time holders. A mere announcement of listing on the main market of LSE, HK and/Shanghai is sufficient to uplift the share price in a big way.

Sincere suggestion to the analysts asking questions in tomorrow’s presentation; kindly refrain from asking onco-pharmacological chemistry queries unless you are experts in oncology/ pharmaceutical science. Such questions do not make any sense.

[dbadvn] 02/3/2021 13:01

Sportii,

I think you have exactly the point.. Co needs to have at least as much focus on commercialization as drug development and needs to make it clear that they are working for the benefit of all stakeholders. Shareholders have been more than patient - time for solid returns .

[sportii] 02/3/2021 12:55

During the final results (4th March), can it be expected for getting answers/clarifications to, at least few of the points and queries mentioned in Nofs’s post above? Hopefully, financial analysts will be seeking answers to questions important for the investors. Asking mere pharmacotherapeutic chemistry questions (like in the previous years) will not be of much help.

[dbadvn] 02/3/2021 11:47

Hopefully recent large shareholders are putting on some pressure.
Last time I saw CH I did make my thoughts on AZN completely plain I think the Junshi relationship has just outed them completely. Must say if I was AZN I would have done the same , they have played a blinder....

[nerdofsteel] 02/3/2021 09:49

"Junshi will continue to be responsible for the promotion of other indications in core areas
--The companies will continue to explore business collaborations in overseas markets including emerging markets"

something must have gone wrong with the HCM/AZ relationship if they are partnering with Junshi. OK, for one drug fine, but the press release implies more collaboration is on the way between the two Co's.

Chi-Med seems to have lost its way:-

Botched CKHH placings
Lost/Had Seroquel taken away from under their noses
Savo PRCC failures
Very very very slow Sav progress in general
No collaborations with western Biopharmas (unlike Beiegene)
No acquisition of large molecule Company or asset within a year (broken promise)
Pulled HK liusting when other Co's continued to list in the same week!
No update on when the listing will be resurrected apart from "it will happen at some point" which is really not quite good enough

Otherwise great clinical progress but it's simply not enough to attract new investors

[nerdofsteel] 02/3/2021 07:35

Interesting - the pace of Savo development has been pedestrian, even by Biotech standards. AZ also appear to have stitched up HCM over Seroquel. it's probably tie for HCM to buy AZ's rights to Savo outright.

I do wish Chi-Med would pull its finger out like Beigene and get some big corporate deals done - they are too conservative and too slow. I'm a long term investor but frustrated the market ignores the Company.

[dbadvn] 01/3/2021 16:29

See : Junshi Biosciences and AstraZeneca join hands to promote cancer drug

AZN partners or Competition ?

I'm going for competition - they have been slow / obstructive all the way on any developments with HCM - even CH admits to being frustrated.

[nerdofsteel] 27/2/2021 17:20

I've been a patient Investor for 10 years and have consistently added to my holding in that time but I think without a listing in Asia they will be continue to be treated with contempt by the market. To Yid's point, they have made incredible progress, 2 drugs approved, a 3rd to be approved shortly (Savo in China) but Savo has disappointed. It was forecast to launch globally for NSCLC & PRCC in 2021, clearly both massive material misses. They also have a China sales team so need to leverage it to detail/market their own and other Co's drugs who dp not have feet on the street in China. That's how Beigene have turned themselves from a $3bn to a $30bn mcap Company in 5 years. Chi-Med have been very disappointing during the same period.

[steeplejack] 26/2/2021 20:25

Completely agree.Maybe the Chinese authorities don't want HCM to "endorse" Hong Kong by filing for a listing there.I suppose we'll just have to put it down to the Alibaba effect.Anyway,i sold a few at 5 quid some weeks back because there's inevitability about the inertia here compounded by the AIM market treating the stock with something approaching contempt.The company seems incapable of meaningful promoting its own cause.Maybe this doesn't merit being treated as a core holding and reluctantly i think i'll sell more on any meaningful price recovery.Oh ,i'll keep a reasonable slug so i can hopefully admonish myself for impatience but one feels you could go away for months and revisit this stock and find it languishing.

[nerdofsteel] 25/2/2021 09:13

that's true Rabid, although NASDAQ control the price here now, thanks to tiny volumes traded in London

[rabiddog] 24/2/2021 16:02

Hcm was on the IG margin list hxxps://www.ig.com/content/dam/publicsites/igcom/uk/210219_IGM_UK_Affected%20Markets%20-%20Non%20TT.pdf probably explains sell off this week

[steeplejack] 24/2/2021 08:22

Market makers treat this stock like an old rag doll.

[its the oxman] 23/2/2021 16:30

Nasty , back to 430p

[fionascott1234] 22/2/2021 15:55

Choppy indeed at 6% stinging drop.

[lauders] 22/2/2021 02:02

Perhaps a bit choppy here this week (?) as HCM are on this list that can be followed from the link in the following useful article:

NofS - If you have confidence in CH and the BOD (given the "hundred 1,000 invested that would seem to be the case) and HCM's products then the coin will drop one day. It may be frustrating but the products and eventual income will dictate the future. I don't have nearly as much as you at stake which is why I can perhaps be more relaxed about it. The "opportunity cost" factor is a real one.

[nerdofsteel] 21/2/2021 09:06

with a few hundred 1,000 invested here and as a long term investor (over 10 years) I am getting a bit frustrated that despite all the progress inc. our first 2 drugs launched in China and our first NDA in the United States for a wholly owned asset our mcap is effectively the same as it was 3 and a half years ago.

I look at Beigene which I contemplated investing in 3 years ago and see their massive uplift in valuation, thanks mainly to large partnership deals and then I ask myself this question:-

Given Chi-Med's huge distribution infrastructure in China, together with its knowledge of the Chinese regulatory pathways, why isn't the company leveraging that to partner with big pharma like Beigene has?

I'll sell when the mcap reaches $20 billion.

[its the oxman] 14/2/2021 15:01

Doesn't want to break above 520p.

[steeplejack] 13/2/2021 21:43

Umm...retreated sharply in the US from hitting new highs.Groundhog day.The company is clearly ‘relaxed’; about its stockmarket perception.Mr Hogg talks the talk but does he walk the walk when it comes to promoting wider investor recognition of the company’s potential.Its not as if I’ve lost money here,on the contrary,but it’s lower quartile in my portfolio and I'm searching for explanations!

[its the oxman] 05/2/2021 13:20

Near the top of our long term sideways trend, break up to 550p (hopefully sets up further gains beyond) would be really positive.

[nerdofsteel] 03/2/2021 07:26

There's certainly a history of the ADR price rising significantly the day prior to news! Only notice of results date today but the Company has been quiet for a while now. I continue to buy!

[lauders] 03/2/2021 01:02

A nice bounce towards the end of the day! Do we have a leaky ship here and news is due shortly? There I was thinking about making a top-up too. Just shows action is better than dwelling too long on one's thoughts!

[nerdofsteel] 21/1/2021 07:06

I have a small holding in Tils.

I've been unhappy for same time that Chi-Med has not a) moved to a Main Market Listing or b) completed its HK or Star Market listing

On the latter point Iam mystified on the delay. They had a prospectus 2 years ago and pulled the listing due to the HK riots, meanwhile plenty of other Biotechs went ahead and have been very very successful in building shareholder value eg, Beigene & Wuxi

Why is this Company always stuck in the slow lane when it comes to listings and also why do we not stroke more deals like Beigene have? Investing here is becoming extremely frustrating.

[steeplejack] 20/1/2021 15:01

By the by,Tiziana’s imminent move to the main market has contributed to a substantial price rise both in the U.K. and on the Nasdaq,a rise of some 20% on the latter exchange.....and it has been higher.

[steeplejack] 20/1/2021 10:51

Market cap of Tiziana is around £300m.Yet,it considers that a main board LSE listing worthwhile,despite what some others might think :)AIM Delisting and Admission to the Standard Listing Segment of Main MarketNew York/London, 20 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary shares (the "Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct Authority ("FCA") (the "Official List") and admission to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange") (together, "Admission").